[1] Butler-Laporte G, De L’Étoile-Morel S, Cheng MP, McDonald EG, Lee TC. MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis. J Infect. 2018; 77(6):489–495.
[2] Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014; 77:50–57.
[3] Ye ZK, Li C, Zhai SD. Guidelines for therapeutic drug monitoring of vancomycin: a systematic review. PLoS One. 2014; 9(6):e99044.
[4] Ji XW, Ji SM, He XR, Zhu X, Chen R, Lu W. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycinin Chinese adult patients. Acta Pharmacol Sin. 2018; 39(2):286–293.
[5] Nelson NR, Morbitzer KA, Jordan JD, Rhoney DH. The Impact of Capping Creatinine Clearance on Achieving Therapeutic Vancomycin Concentrations in Neurocritically III Patients with Traumatic Brain Injury. Neurocrit Care. 2019; 30(1):126–131.
[6] Padgett D, Ostrenga A, Lepard L. Comparison of methods of estimating creatinine clearance in pediatric patients. Am J Health Syst Pharm. 2017; 74(11):826–830.
[7] Romão CM, Pereira RC, Shimizu MHM, Furukawa LNS. N-acetyl-l-cysteine exacerbates kidney dysfunction caused by a chronic high-sodium diet in renal ischemia and reperfusion rats. Life Sci. 2019; 231:116544.
[8] Wang K, Kestenbaum B. Proximal Tubular Secretory Clearance: A Neglected Partner of Kidney Function. Clin J Am Soc Nephrol. 2018; 13(8):1291–1296.
[9] Rutter WC, Hall RG, Burgess DS. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin. Am J Health Syst Pharm. 2019; 76(16):1211–1217.
[10] Pokorná P, Šíma M, Černá O, Allegaert K, Tibboel D, Slanař O. Actual body weight-based vancomycin dosing in neonates. J Chemother. 2019; 31(6):307–312.
[11] Vitolo E1, Santini E, Salvati A, Volterrani D, Duce V, Bruno RM, Solini A. Metabolic and Hormonal Determinants of Glomerular Filtration Rate and Renal Hemodynamics in Severely Obese Individuals. Obes Facts. 2016; 9(5):310–320.
[12] Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18–55.
[13] Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother. 2018; 73(11):3081–3086.
[14] Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015; 35(2):127–139.
[15] Disease control Ministry of Health of the People’s Republic of China. The Guidelines of Chinese Adult Overweight and Obesity Prevention and Control. Beijing: People’s Medical Publishing House. 2006; p. 1–3.
[16] Eknoyan G, Levin N. NKF-K/DOQI Clinical Practice Guidelines: Update 2000. Foreword. Am J Kidney Dis. 2001; 37(1 Suppl 1):S5–6.
[17] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31–41.
[18] Heble DE Jr, McPherson C, Nelson MP, Hunstad DA. Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy. 2013; 33(12):1273–1277.
[19] https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. (February 16, 2018).
[20] Hayes A, Gearon E, Backholer K, Bauman A, Peeters A. Age-specific changes in BMI and BMI distribution among Australian adults using cross-sectional surveys from 1980 to 2008. Int J Obes (Lond). 2015; 39(8):1209–1216.